About Kainos Medicine

About company

Kainos Medicine, Inc., a clinical-stage company, researches and develops various medicines for cancers, and brain and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is under Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is under Phase II clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor, enhancer of Zeste Homolog 2 inhibitor, and BRD4 inhibitor; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia.